Abstract:Background: Advanced prostate cancer (PCa) is a leading cause in cancer death and can elicit significant morbidity and mortality. A common treatment modality for advanced PCa is radiation therapy (RT). Currently, salvage of local disease recurrence after RT is a major clinical problem. Emerging evidence indicates the importance of the immune system in governing RT response. In support of this, immune checkpoint inhibitors (ICIs), which enhance immune activation, have demonstrated clinical therapeutic promise in combination with RT in certain advanced cancers. Irradiation (IR) combined with ICIs may prime the immune system to recognize and target recurrent cancer. Purpose: Investigate the therapeutic efficacy of ICIs in combination with RT for radiorecurrent PCa in a syngeneic pre-clinical model. Methods: TRAMP-C2 cells were treated with 10 Gy of radiation over 5 fractions (similar to clinical hypofractionated (HF) schedule) to generate TRAMP-C2 HF cells. Immune-competent mice were transplanted subcutaneously with TRAMP-C2 HF cells. Once tumors reached palpable size, mice were administered either ICIs (αPDL1 or αCTLA4) alone or in combination with RT. Tumor volume was monitored to determine the treatment effect. Correlative studies on excised tumors and secondary lymphoid organs included flow cytometry and NanoString gene expression panel to evaluate immunological mechanisms that contribute to anti-tumor effects[SL1]. Results: TRAMP-C2 HF cells were validated for radiation resistance and exhibited a more aggressive phenotype (reduction in senescence, increase in clonogenicity) similar to clinically recurrent PCa. Radiation resistance of TRAMP-C2 HF tumors was validated in vivo. Administration of αPDL1 and αCTLA4 as monotherapy or in combination did not achieve significant tumor growth delay compared to control. IR alone produced an observable tumor growth delay compared to ICIs alone. The combination of αPDL1 and IR did not yield additional growth delay compared to IR alone. Strikingly, significant tumor growth delay was seen with the combination of IR and αCTLA4 compared to IR alone, while also resulting in complete cure in a third of the mice. NanoString analysis of lymph nodes from mice treated with αCTLA4 and IR vs. IR alone demonstrated differential expression of genes regulating CD molecules, interleukins, and T-cell functions. Furthermore, enrichment of CD45 and CD8a RNA following αCTLA4 and IR was observed. Validation by flow cytometry is currently ongoing. Conclusion: We generated the first syngeneic radiorecurrent PCa model and demonstrated that combining αCTLA4 and IR results in synergistic tumor response. Combined therapy resulted in augmented immune response, most notably enhancement of CD8 T cell activity. Significance: These findings contribute to our understanding of immunological events associated with RT and ICIs in the context of radiorecurrent PCa and support new avenues for salvage therapy in clinical trials. Citation Format: Hanzhi Wang, Xiaoyong Huang, Stepahnie D White, Linsey Gong, Tera N Petchiny, Hans Chung, Emmanouil Fokas, Robert S Kerbel, Stanley K Liu. Combination of anti-CTLA4 and radiation induce synergistic tumor control in radiorecurrent prostate cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr A025.

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Radiation-Induced Apoptosis along with Local and Systemic Cytokine Elaboration is Associated with Dc Plus Radiotherapy-Mediated Renal Cell Tumor Regression

Effect of Treatment with Local Administration of Dendritic Cells Combination Radiotherapy on the Expression of Bcl-2 and Bax in Renal Tumor Bearing Mice

Targeting the dendritic cell-secreted immunoregulatory cytokine CCL22 alleviates radioresistance

Impact of 5-Fu/oxaliplatin on Mouse Dendritic Cells and Synergetic Effect with a Colon Cancer Vaccine.

Enhancement of Sensitivity to Chemo/Radiation Therapy by Using Mir-15B Against DCLK1 in Colorectal Cancer.

The Synergistic Anti-Tumor Effect of Radiofrequency and Cytokine-Induced Killer Cells in Mice

Irradiated Engineered Tumor Cell-Derived Microparticles Remodel the Tumor Immune Microenvironment and Enhance Antitumor Immunity.

Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor

Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy

Combined Radiation Therapy and Dendritic Cell Vaccine for Treating Solid Tumors with Liver Micro‐metastasis

Dynamically Expressed Microrna-15B Modulates the Activities of CD8 + T Lymphocytes in Mice with Lewis Lung Carcinoma

L-Arginine and Docetaxel Synergistically Enhance Anti-Tumor Immunity by Modifying the Immune Status of Tumor-Bearing Mice

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy

Modulating the Tumor Microenvironment Via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.

Abstract A025: Combination of anti-CTLA4 and radiation induce synergistic tumor control in radiorecurrent prostate cancer

Deciphering colorectal cancer radioresistance and immune microrenvironment: unraveling the role of EIF5A through single-cell RNA sequencing and machine learning

Effect of Intratumoral Injection of Dendritic Cells in Combination with Radiotherapy on the Expression of TNF-α in a Mouse Model of Renal Carcinoma

Immunotherapy Targeting Different Immune Compartments in Combination with Radiation Therapy Induces Regression of Resistant Tumors

Antitumor Immunity Augmented by Combining Radiofrequency Ablation with Anti–CTLA-4 Therapy in a Subcutaneous Murine Hepatoma Model